|
2026
|
P/S
|
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, ... |
|
|
P/S
|
Prescription-only pharmaceutical preparations and substances for the treatment of neurological di... |
|
|
P/S
|
Pharmaceutical substances and preparations for the treatment of oncological diseases and disorders |
|
|
P/S
|
Pharmaceutical substances and preparations for the treatment of oncological diseases and disorders |
|
|
P/S
|
Pharmaceutical substances and preparations for the treatment of oncological diseases and disorders. |
|
|
P/S
|
Pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of cancer; pharm... |
|
|
P/S
|
Educational services, namely providing teaching and training in the field of diverse and inclusiv... |
|
2025
|
P/S
|
Physician incentive award program to promote physician loyalty which provides incentives and rewa... |
|
|
Invention
|
Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis.
Aspects of the application provide... |
|
|
Invention
|
Levodopa and carbidopa intestinal gel and methods of use.
The present disclosure provides (a) a ... |
|
|
Invention
|
Extended release upadacitinib formulations.
The disclosure describes extended release solid dosa... |
|
|
Invention
|
Dosing regimens for elagolix.
The present invention relates to dosing regimens for GnRH receptor... |
|
|
Invention
|
Methods of treating heavy menstrual bleeding.
The present invention relates to the method of tre... |
|
|
Invention
|
Methods of treating pancreatic tumors expressing certain biomarkers. Provided herein are methods ... |
|
|
Invention
|
Anti-sars-cov-2 antibodies and uses thereof.
Provided herein are monoclonal antibodies that spec... |
|
|
Invention
|
Devices and methods for delivering a beneficial agent to a user.
Drug delivery reservoir for del... |
|
|
Invention
|
1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors.
The presen... |
|
|
Invention
|
Anti-cd79b antibody drug conjugates. The present disclosure relates to anti-CD79b antibodies and ... |
|
|
Invention
|
Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis. Aspects of the application provide ... |
|
|
Invention
|
Enzyme compositions with reduced viral and microbial contamination.
The present invention pertai... |
|
|
Invention
|
Wearable automatic injection system and apparatus.
A wearable automatic injection device is prov... |
|
|
Invention
|
Treating spondyloarthritic and psoriatic conditions with upadacitinib.
Provided are methods for ... |
|
|
Invention
|
Tiparp inhibitor compounds. The present disclosure provides for compounds of Formula (I), and pha... |
|
|
Invention
|
Tiparp inhibitor compounds.
The present disclosure provides for compounds of Formula (I), and ph... |
|
|
Invention
|
Methods of treatment using anti-sez6 antibody drug conjugates. The present application pertains t... |
|
|
Invention
|
Methods of treatment using anti-sez6 antibody drug conjugates.
The present application pertains ... |
|
|
Invention
|
Lpar1 inhibitors.
Provided herein are compounds of Formula (I), compounds of Formula (II) and ph... |
|
|
Invention
|
Lpar1 inhibitors. Provided herein are compounds of Formula (I), compounds of Formula (II) and pha... |
|
|
Invention
|
Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)... |
|
|
Invention
|
Upadacitinib for use in the treatment of giant cell arteritis. The present disclosure is directed... |
|
|
Invention
|
Anti-alpha-4-beta-7 antibodies.
The present disclosure provides anti-α4β7 antibodies that bind h... |
|
|
Invention
|
Bispecific binding molecules.
The present disclosure provides novel bispecific molecules that bi... |
|
|
Invention
|
Anti-tau antibodies. The present disclosure provides anti-tau antibodies, including compositions ... |
|
|
Invention
|
Pharmaceutical formulations for subcutaneous administration.
The present disclosure relates to c... |
|
|
Invention
|
Pump, motor and assembly for beneficial agent delivery.
Pump includes a motor, a cam shaft coupl... |
|
|
Invention
|
Clostridium botulinum neurotoxin serotype a compositions and improved drying processes. Clostridi... |
|
|
Invention
|
Clostridium botulinum neurotoxin serotype a compositions and improved drying processes.
Provided... |
|
|
Invention
|
Lutikizumab for use in a treatment of hidradenitis suppurativa. The present disclosure relates to... |
|
2024
|
Invention
|
High concentration risankizumab formulations. The present disclosure relates to novel antibody fo... |
|
|
Invention
|
Salts and crystalline forms of an apoptosis-inducing agent.
Salts and crystalline forms of 4-(4-... |
|
|
Invention
|
Psma-steap1 dual variable domain immunoglobulin (dvd-ig) molecules and drug conjugates.
The pres... |
|
|
Invention
|
Macrocyclic mcl-1 inhibitors and methods of use.
The present disclosure provides for compounds o... |
|
|
Invention
|
Pyrimidines for degrading bruton's tyrosine kinase.
The present invention provides for compounds... |
|
|
Invention
|
Methods for treating spinal cord injury and pain.
Disclosed herein are anti-RGMa antibodies and ... |
|
|
Invention
|
Fused bicyclic compounds for the treatment of disease.
Described herein are fused bicyclic compo... |
|
|
Invention
|
Anti-egfr antibody drug conjugates.
The invention relates to anti-Epidermal Growth Factor Recept... |
|
|
Invention
|
Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary ... |
|
|
Invention
|
Methods of treating amyotrophic lateral sclerosis. The present disclosure provides herein, inter ... |
|
2023
|
Invention
|
Carrying vest |
|
|
Invention
|
Risankizumab compositions.
The present disclosure relates, in part, to risankizumab compositions... |
|
2022
|
Invention
|
Process of making apoptosis-inducing agents.
Provided herein is a process for the preparation of... |
|
|
Invention
|
Protein tyrosine phosphatase targeting ligands.
Provided herein are compounds, compositions, and... |
